2019 Novel Coronavirus (COVID-19)

South Dakota Department of Health

December 17, 2020

We will begin in just a few moments. Thanks!
This is an **emerging, rapidly evolving situation**. Information in this presentation is current as of December 16, 2020. Please check the South Dakota Department of Health website for the most current information and guidance.

[COVID.sd.gov](https://COVID.sd.gov)
Agenda

- Situation Update
- Laboratory Guidance
- Long Term Care
- Vaccination Update
- Community Mitigation
- Supply Chain Management
- On-going Communications
- Q&A Session
% RT-PCR Test Positivity Rate by Date Reported to SD-DOH: This graph shows % RT-PCR Test Positivity Rate which is equal to the number of positive RT-PCR tests divided by total RT-PCR tests, within the specified period of time.
COVID-19 Dashboard Updates

**Vaccines tab**

- **Total Doses Administered**: 405
- **Total Persons Administered a Vaccine**: 405

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Number of Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
<td>405</td>
</tr>
</tbody>
</table>

**Deaths tab**

- **Deaths among people with COVID-19**: 1,300
- **Deaths caused by COVID-19**
  - *Updated weekly on Monday:*
  - **1,159**
- **Cases Among Long Term Care Residents**: 2,926
- **Deaths among Long Term Care Residents with COVID-19**: 632

**Deaths among people with COVID-19 by Date of Death**

[Distribution graph showing date of death for COVID-19 cases]
Timeline of Case Milestone in South Dakota

March 10: First COVID-19 cases in South Dakota

10,000 cases milestone: + 157 days
20,000 cases milestone: + 41 days
30,000 cases milestone: + 20 days
40,000 cases milestone: + 13 days
50,000 cases milestone: + 9 days

60,000 cases milestone: + 7 days
70,000 cases milestone: + 8 days
80,000 cases milestone: + 10 days
90,000 cases milestone: + 12 days
Coronavirus Situation (as of December 16, 2020)

- **International**
  - 72,196,732 confirmed cases
  - 1,630,521 deaths
- **United States** (50 states + DC)
  - 16,519,668 confirmed cases
  - 302,992 deaths
- **South Dakota**
  - 92,603 confirmed and probable cases
  - 1,300 deaths
  - 80,316 recovered cases
Epidemiologic “Epi” Curve of COVID-19 Cases, by Date Reported to SD-DOH

As of December 16, 2020
COVID-19 Case Map, by County

As of December 16, 2020

Substantial Community Spread

- Aurora
- Beadle
- Bennett
- Bon Homme
- Brookings
- Brown
- Brule
- Buffalo
- Butte
- Charles Mix
- Clark
- Clay
- Codington
- Corson
- Custer
- Davison
- Day
- Deuel
- Dewey
- Douglas
- Edmunds
- Fall River
- Faulk*
- Grant
- Gregory
- Haakon
- Hamlin
- Hanson
- Hughes
- Hutchinson
- Jackson
- Kingsbury
- Lake
- Lawrence
- Lincoln
- Lyman
- Marshall
- McCook
- Meade
- Mellette
- Miner
- Minnehaha
- Moody
- Oglala Lakota
- Pennington
- Perkins
- Potter
- Roberts
- Sanborn
- Spink
- Todd
- Tripp
- Turner
- Union
- Walworth
- Yankton
- Ziebach

*New counties
General Testing Recommendations

Medical providers are recommended to test individuals with signs and symptoms compatible with COVID-19 infection, including:

- Fever or chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue
- Muscle or body aches
- Headache
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea


As of June 18, 2020
Reporting COVID-19 Tests to SD-DOH

• **Reminder:** Coronavirus respiratory syndromes are a Category I disease

• Report *immediately* on suspicion of disease

• Reporting mechanisms:
  • Electronic Laboratory Report (ELR) – HL7 message to SD Health Link (health information exchange)
  • Flat file (CSV) – Secure email
  • Disease reporting website – [sd.gov/diseasereport](http://sd.gov/diseasereport)
  • Fax – 605.773.5509
COVID-19 Mortality Among American Indian and Alaska Native Persons — 14 States, January–June 2020

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>AI/AN deaths</th>
<th>White deaths</th>
<th>AI/AN:White rate ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%)**</td>
<td>Rate†† (95% CI)</td>
<td>No. (%)§§</td>
</tr>
<tr>
<td>Total*</td>
<td>1,134 (100)</td>
<td>55.8 (52.5–59.3)</td>
<td>18,815 (100)</td>
</tr>
<tr>
<td>Sex*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>621 (55)</td>
<td>66.4 (60.9–72.1)</td>
<td>9,775 (52)</td>
</tr>
<tr>
<td>Women</td>
<td>513 (45)</td>
<td>46.8 (42.8–51.1)</td>
<td>9,035 (48)</td>
</tr>
<tr>
<td>Missing</td>
<td>0</td>
<td>—</td>
<td>5</td>
</tr>
<tr>
<td>Age group, yrs§§</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20–29</td>
<td>27 (2)</td>
<td>6.3 (4.2–9.2)</td>
<td>31 (0.2)</td>
</tr>
<tr>
<td>30–39</td>
<td>72 (6)</td>
<td>19.8 (15.5–25.0)</td>
<td>91 (0.5)</td>
</tr>
<tr>
<td>40–49</td>
<td>99 (9)</td>
<td>34.0 (27.6–41.3)</td>
<td>199 (1)</td>
</tr>
<tr>
<td>50–59</td>
<td>200 (18)</td>
<td>73.9 (64.1–84.9)</td>
<td>870 (5)</td>
</tr>
<tr>
<td>60–69</td>
<td>268 (24)</td>
<td>127.7 (112.8–143.9)</td>
<td>2,337 (12)</td>
</tr>
<tr>
<td>70–79</td>
<td>235 (21)</td>
<td>218.1 (191.1–247.8)</td>
<td>4,514 (24)</td>
</tr>
<tr>
<td>≥80</td>
<td>230 (20)</td>
<td>488.3 (427.3–555.7)</td>
<td>10,767 (57)</td>
</tr>
<tr>
<td>Missing</td>
<td>3</td>
<td>—</td>
<td>6</td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence interval; COVID-19 = coronavirus disease 2019.
* Rates are age-adjusted to the 2000 U.S. standard population.

https://www.cdc.gov/mmwr/volumes/69/wr/mm6949a3.htm?s_cid=mm6949a3_x
% of Total Cases by Age Group; Hospitalizations, and Deaths per Age Group

- 0-9 Years
- 10-19 Years
- 20-29 Years
- 30-39 Years
- 40-49 Years
- 50-59 Years
- 60-69 Years
- 70-79 Years
- 80+ Years

- % of Total Cases
- % of Age-specific Cases Hospitalized
- % of Age-Specific Cases Died
Selected CDC Updates

Available at: https://www.cdc.gov/coronavirus/2019-ncov/whats-new-all.html


Laboratory Guidance
Statewide Priority Populations for SARS-CoV-2 Testing

It is a statewide priority that ALL individuals with symptoms of COVID-19 be tested for SARS-CoV-2 with the recommendation from a health care provider.

• Hospitalized individuals
• Healthcare workers, first responders, and active military
• Critical infrastructure workers in food manufacturing and agriculture
• Individuals in communal living settings like long-term care and correctional facilities
• Underinsured or uninsured individuals
• Low-income individuals or individuals unable to pay for testing
• Homeless individuals
SDPHL SARS-CoV-2 Testing Priorities

- **Symptomatic** hospitalized patients
- **Symptomatic** healthcare workers, first responders, and active military
- **Symptomatic** individuals in congregate living settings like LTC facilities
- **Symptomatic** individuals with no way to pay for testing
- **Asymptomatic** participants in state-sponsored sentinel surveillance programs
- **Confirmation testing** for the following scenarios:
  - Symptomatic individual in a high-prevalence setting with negative antigen result
  - Asymptomatic individual in a low-prevalence setting with positive antigen result
SARS-CoV-2 Antigen Testing: Abbott BinaxNOW

- SDDOH will receive a weekly federal allocation of Abbott BinaxNOW tests into early 2021.

- SDDOH continues to accept requests for BinaxNOW antigen cards
  - Joan.Adam@state.sd.us
  - Laurie.Gregg@state.sd.us
  - Tim.Southern@state.sd.us

- Inquiries for BinaxNOW resources can also be directed to:
  - Dorothy.Ahten@abbott.com
SARS-CoV-2 Antigen Testing: QIAGEN QIAreach

- In response to our solicitation in mid-November, SDDOH received requests to place QIAGEN resources at over 160 locations in SD.
- SDDOH still awaits notification of FDA EUA approval for the QIAreach Antigen Test.
- SDDOH is tentatively planning to roll-out QIAGEN resources in early January.
- Questions about QIAGEN resources can be sent to:
  - Laurie.Gregg@state.sd.us
  - Tim.Southern@state.sd.us
State-Sponsored COVID-19 Saliva Testing

https://doh.sd.gov/COVID/
• SDPHL will perform high-priority testing on Thursday, December 24
• SDPHL will be closed Friday, December 25
• SDPHL will perform high-priority testing on Saturday, December 26
• SDPHL will be closed on Sunday, December 27
• SDPHL will resume normal operations on Monday, December 28
• SDPHL will be closed for the New Year Holiday Friday, January 1
Happy Holidays from the State Public Health Laboratory
Long Term Care
Disease Impact – United States

as of 11.29.20

Resident and Staff Cases and Deaths

TOTAL RESIDENT COVID-19 CONFIRMED CASES
377,510

TOTAL RESIDENT COVID-19 DEATHS
76,542

TOTAL STAFF COVID-19 CONFIRMED CASES
322,690

TOTAL STAFF COVID-19 DEATHS
1,162

Long Term Care in South Dakota
Nursing Homes and Assisted Living Centers

- Current Total of LTC Facilities with Case – 89*
- Cumulative Total LTC Facilities with Case – 210
- Cumulative Total Resident Active Cases – 630*
- Cumulative Total Resident Cases – 2,877
- Cumulative Total Resident Deaths – 616
- Total Active Cases in Staff – 258*
- Cumulative Total Case in Staff – 1,092
- Cumulative Total Staff Hospitalized – 24

*self-reported by touch-base calls as of 12.15.2020 - all data is provisional
Resident Cases and Deaths per 1,000 Residents

28.8 cases /1,000 residents

as of week of 11/29/20
15.1 deaths/1,000 residents

as of 11/22/20
Statewide data as of 12.15.20 – all cases reported
We must all remain vigilant.
The Core Principles of COVID-19 Infection Prevention

- **Screening** of all who enter the facility for signs and symptoms of COVID-19 (e.g., temperature checks, questions or observations about signs or symptoms), and denial of entry of those with signs or symptoms
- **Hand hygiene** (use of alcohol-based hand rub is preferred)
- **Face covering or mask** (covering mouth and nose)
- **Social distancing** at least six feet between persons
- **Instructional signage** throughout the facility and proper **visitor education** on COVID-19 signs and symptoms, infection control precautions, other applicable facility practices (e.g., use of face covering or mask, specified entries, exits and routes to designated areas, hand hygiene)
- **Cleaning and disinfecting** high frequency touched surfaces in the facility often, and designated visitation areas after each visit
- **Appropriate use of Personal Protective Equipment (PPE)**
- **Effective cohorting** of residents (e.g., separate areas dedicated COVID-19 care)
- **Resident and staff testing** are accessible
Resources for Long Term Care


In addition, the CMS Current Emergencies webpage for the most up to date information: [https://www.cms.gov/About-CMS/Agency-Information/Emergency/EPREO/Current-Emergencies/Current-Emergencies-page](https://www.cms.gov/About-CMS/Agency-Information/Emergency/EPREO/Current-Emergencies/Current-Emergencies-page).

We encourage all nursing homes to monitor the CDC website for information and resources, including the following site: “Preparing for COVID-19 in Nursing Homes” ([https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html)).
Resources for Long Term Care

Project Echo Clinical Rounds - including a series of sessions focused on nursing facility care: https://hsc.unm.edu/echo/institute-programs/covid-19-response/us-covid19/hhs-aspr/

Here is the link to the Nursing Home Resource Center: https://www.cms.gov/nursing-homes;

and the specific link to CMS training designed to help staff combat the spread of COVID-19 in nursing homes: https://qsep.cms.gov/welcome.aspx
Resources for Long Term Care

Project Echo Clinical Rounds - including a series of sessions focused on nursing facility care: https://hsc.unm.edu/echo/institute-programs/covid-19-response/us-covid19/hhs-aspr/

Here is the link to the Nursing Home Resource Center: https://www.cms.gov/nursing-homes;

and the specific link to CMS training designed to help staff combat the spread of COVID-19 in nursing homes: https://qsep.cms.gov/welcome.aspx
CMS Targeted COVID-19 Training for Frontline Nursing Home Staff.

CMS Targeted COVID-19 Training for Nursing Home Management.

Financial incentive for employees of eligible nursing homes and assisted living centers to complete the CMS training. This incentive is available for all employees of a Nursing Home and or an Assisted Living Center. A pre-test and post-test are required.

The grant will be with the facility. The provider will pay their employee. Please note, the same timeline applies to all providers.

• Email Lori Konst at Lori.Konst@state.sd.us you are interested in this incentive for your staff by December 16, 2020.
• Grants will be issued via DocuSign to the provider by December 18.
• The employee must show proof of completion to their facility administrator by December 21. Providers should retain a list of those staff completing the training. The incentive will also be paid to employees who have already completed the training.
• Facilities must invoice the Department of Health by COB December 22, 2020 for payment. The provider must provide us the number of staff, with a list of staff, trained in order to receive reimbursement. The DOH does not need the certificate.

Please contact Pam Evenson at email Pam.Evenson@state.sd.us if you have questions with accessing the CMS training.
Holiday Visitation – During COVID-19 Pandemic

- Focus efforts on encouraging families to keep residents safe during the holidays.

- Educate families on the risk of taking loved ones out of the facility.

- Determine other ways to conduct visitation – virtual, not the same but may keep the resident safe.


- Follow facility policy for visitation to include holiday timeframes.

- Upon the resident’s return place them on observation as if a new admit.
  - The resident is not cohorted with positive or suspected COVID cases.
  - The resident is placed in observation and monitored for COVID signs and symptoms.

*With the exception of Memo 20-39, the above are recommendations voiced by CMS. These are not requirements/rules/regulations and are not in writing.*
Vaccination Update
Pfizer Vaccine Side Effects

- Injection site pain, swelling, redness
- Tiredness
- Muscle pain
- Chills
- Joint pain
- Fever
- Nausea
- Feeling unwell
- Swollen lymph nodes
Who should not get the Pfizer vaccine

You should not get the Pfizer-BioNTech COVID-19 Vaccine if you:

• had a severe allergic reaction after a previous dose of this vaccine

• had a severe allergic reaction to any ingredient of this vaccine
Pfizer vaccine Ingredients

- mRNA, lipids ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate),
- 2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide,
- 1,2-Distearoyl-sn-glycero-3-phosphocholine, and cholesterol,
- potassium chloride,
- monobasic potassium phosphate,
- sodium chloride,
- dibasic sodium phosphate dihydrate,
- sucrose
Pfizer Vaccine Administration timing

• 2 dose series 3 weeks apart

• Administration of 2\textsuperscript{nd} dose within 4-day grace period (day 17-21) considered valid

• If >21 days since 1\textsuperscript{st} dose, 2\textsuperscript{nd} dose should be administered at earliest opportunity, but no doses need to be repeated
Coadministration with other vaccines

- Pfizer-BioNTech COVID-19 vaccine should be administered alone with a minimum interval of 14 days before or after administration with any other vaccines
  - Due to lack of data on safety and efficacy of the vaccine administered simultaneously with other vaccines

- If Pfizer-BioNTech COVID-19 vaccine is inadvertently administered within 14 days of another vaccine, doses do not need to be repeated for either vaccine
Vaccination Efforts in South Dakota

- 7800 doses have arrived between Monday and Tuesday
- SD will receive 14,600 Moderna doses next week.
COVID-19 Vaccine Provider Education Update

• **New**
  – Pfizer specific vaccination information
    • Constituting the vaccine
    • Storage & handling
    • Training videos
    • Other tools and resources
  – Pfizer Emergency Use Authorization
  – EUA available on our website
  – Fact sheet to be given to recipient or caregiver
FACT SHEET FOR RECIPIENTS AND CAREGIVERS

EMERGENCY USE AUTHORIZATION (EUA) OF
THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS
DISEASE 2019 (COVID-19)
IN INDIVIDUALS 16 YEARS OF AGE AND OLDER

You are being offered the Pfizer-BioNTech COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2. This Fact Sheet contains information to help you understand the risks and benefits of the Pfizer-BioNTech COVID-19 Vaccine, which you may receive because there is currently a pandemic of COVID-19.

The Pfizer-BioNTech COVID-19 Vaccine is a vaccine and may prevent you from getting COVID-19. There is no U.S. Food and Drug Administration (FDA) approved vaccine to prevent COVID-19.

Read this Fact Sheet for information about the Pfizer-BioNTech COVID-19 Vaccine. Talk to the vaccination provider if you have questions. It is your choice to receive the Pfizer-BioNTech COVID-19 Vaccine.

The Pfizer-BioNTech COVID-19 Vaccine is administered as a 2-dose series, 3 weeks apart, into the muscle.

The Pfizer-BioNTech COVID-19 Vaccine may not protect everyone.

This Fact Sheet may have been updated. For the most recent Fact Sheet, please see www.covidvaccine.com.

WHAT YOU NEED TO KNOW BEFORE YOU GET THIS VACCINE?

WHAT IS COVID-19?
COVID-19 disease is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not been seen before. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory illness that can affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.

WHAT IS THE PFIZER-BIONTECH COVID-19 VACCINE?
The Pfizer-BioNTech COVID-19 Vaccine is an unapproved vaccine that may prevent COVID-19. There is no FDA-approved vaccine to prevent COVID-19.
FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE
(VACCINATION PROVIDERS)

EMERGENCY USE AUTHORIZATION (EUA) OF
THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS
DISEASE 2019 (COVID-19)

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use
Authorization (EUA) to permit the emergency use of the unapproved product,
Pfizer-BioNTech COVID-19 Vaccine, for active immunization to prevent
COVID-19 in individuals 16 years of age and older.

SUMMARY OF INSTRUCTIONS FOR COVID-19 VACCINATION PROVIDERS

Vaccination providers enrolled in the federal COVID-19 Vaccination Program must
report all vaccine administration errors, all serious adverse events, cases of
Multisystem Inflammatory Syndrome (MIS) in adults and children, and cases of
COVID-19 that result in hospitalization or death following administration of
Pfizer-BioNTech COVID-19 Vaccine. See “MANDATORY REQUIREMENTS FOR
PFIZER-BIOTECH COVID-19 VACCINE ADMINISTRATION UNDER
EMERGENCY USE AUTHORIZATION” for reporting requirements.

The Pfizer-BioNTech COVID-19 Vaccine is a suspension for intramuscular injection
administered as a series of two doses (0.3 mL each) 3 weeks apart.

See this Fact Sheet for instructions for preparation and administration. This Fact
Sheet may have been updated. For the most recent Fact Sheet, please see

For information on clinical trials that are testing the use of the Pfizer-BioNTech
COVID-19 Vaccine for active immunization against COVID-19, please see
www.clinicaltrials.gov.

DESCRIPTION OF COVID-19

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the
novel coronavirus, SARS-CoV-2, that appeared in late 2019. It is predominantly a
respiratory illness that can affect other organs. People with COVID-19 have
reported a wide range of symptoms, ranging from mild symptoms to severe illness.
Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may
include: fever or chills; cough; shortness of breath; fatigue; muscle or body aches;
headache; new loss of taste or smell; sore throat; congestion or stuffy nose;
nausea or vomiting; diarrhea.
COVID-19 Vaccine Provider Education Update

• Education Plan
  – Please complete provider education
  – No need to print module certificates
    • Unless you are a VFC Coordinator
  – Please check provider website 2x weekly for updates
COVID-19 Vaccine Provider Education Update

• Attestations
  – To be signed by:
    • COVID-19 vaccination coordinator as listed on enrollment form
    • One attestation covers all vaccinators at site
  – Submit to:  DOHCOVIDProviderEducation@state.sd.us.
    • Will send receipt acknowledging completion
COVID-19 Vaccine Provider Education Update

• Vaccine Documentation
  – Within 24 hours
  – Doses administered and remaining inventory
    • Must be documented in SDIIS
    • Must be documented in Vaccine Finder
  – Retain vaccination records at least 3 years
COVID-19 Vaccine Provider Education Update

• VAERS Documentation
  – Adverse reactions

• V-safe information
  – CDC requests that we promote
Community Mitigation
UPDATES

- South Dakota FAQs: Symptoms, potential exposure, socializing risks, food safety, Care19 Diary app. and general resources. Printable PDF
- South Dakota COVID-19 News
- NEW! COVID-19 Media Briefing Archives
- NEW! Updated Quarantine Guidelines
- Risks & Benefits: Considerations for Social Activities during COVID-19
- COVID-19 Contact Tracing
- Frequently Asked Questions (CDC)
- South Dakota’s “Back to Normal” Plan | Spanish
- Great Plains Tribal Chairman’s Health Board COVID-19 Resources
- Interested in volunteering your services? Join the State Emergency Registry of Volunteers for South Dakota.
- What should I do? Infographic
- COVID-19 Testing Facts
- Guidance on interpreting COVID-19 Test Results
- COVID-19 Symptoms and Screening App and Website from Apple (in partnership with CDC and the White House).

SCHOOLS, DAYCARES & YOUTH PROGRAMS

- Reopening Schools Checklist
- Guidelines for School Buses
- Guidance for Food Concession Stands at Schools and Temporary Events
- Starting Well 2020 (SD DOE)
- Information for Public Universities and Special Schools (SD Board of Regents)
- COVID-19 Definitions
- NEW! Checklists to Guide Parents, Guardians, and Caregivers (CDC)
  - In-Person Learning Checklist
  - Virtual or At-Home Learning Checklist
COVID-19 VACCINE INFORMATION

HEALTHCARE PROVIDERS

South Dakota COVID-19 Vaccination Plan
COVID-19 Vaccination FAQs
Benefits of Getting a COVID-19 Vaccine (CDC)

PUBLIC

Click here to find out more about Operation Warp Speed from the U.S. Department of Defense.

Supply Chain Management
All requests for PPE from DOH must be:

- Emailed to COVIDResourceRequests@state.sd.us,
- Faxed to 605.773.5942, or
- Called in to 605.773.3048 to ensure prioritization and coordination of requests.

- Do not duplicate your request by using all three means of communication.

- Any requests received through any other email or number will all be directed to email COVIDResourceRequests@state.sd.us OR call 605.773.3048 and requesting entities must provide information regarding their current facility status.
On-going Communication
Helpful sources of information:

covid.sd.gov

coronavirus.gov

• SD COVID-19 Help Line: 800-997-2880
Communications

- SD-HAN: sdhan.sd.gov
- Epi Listserv
- Lab Listserv
- HAI Listserv
- OLC Listserv

Visit covid.sd.gov to subscribe
Questions?

Follow-up after the webinar
COVID Helpline: 800-997-2880
Epidemiology: 605-773-3737
Laboratory: 605-773-3368

COVID.sd.gov
COVIDSD@state.sd.us